Australia Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Australian diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs) and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

Australia Diabetes Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Australia Diabetes Drugs and Devices Market Size

Australia Diabetes Drugs and Devices Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2019 - 2023
CAGR 3.00 %

Major Players

Australia Diabetes Drugs and Devices Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Australia Diabetes Drugs and Devices Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Australia Diabetes Drugs and Devices Market Analysis

The Australia Diabetes Drugs and Devices Market is expected to register a CAGR of greater than 3% during the forecast period.

The COVID-19 outbreak has accelerated the expansion of the Australian diabetes drug market. People with diabetes infected with COVID-19 can develop high blood sugar levels, irregular blood sugar fluctuations, and diabetic complications. There have been 9,235,681 confirmed COVID-19 cases in Australia since the pandemic began in July 2022, according to the Australian government's Department of Health and Aged Care. The prevalence of diabetes in adults with COVID-19 may be higher than that of patients with type 1 (T1DM) or type 2 (T2DM) diabetes, especially when glycemic control is poor. They are leading to a significant increase in the severity and mortality of cancer. On the other hand, emerging hyperglycemia and diabetes (both T1DM and T2DM) associated with COVID-19 are increasingly recognised and associated with poor prognosis. Patients' blood glucose levels should be checked and maintained regularly to minimize exacerbations, highlighting the importance of drug therapy in diabetes treatment.

Obesity, poor diet, and lack of exercise contribute to the increasing number of newly diagnosed cases of type 1 and 2 diabetes. Rapid increases in the incidence and prevalence of diabetes and healthcare costs in developed countries indicate increased use of diabetes care products. In addition, the rising incidence of diabetes and increasing use of insulin-delivery devices are driving the expansion of the market. Leading manufacturers focus on technological advances and developing improved products to gain significant market share.

Thus, the above factors are expected to drive the market growth over the forecast period.

Australia Diabetes Drugs and Devices Industry Overview

Manufacturers have constantly innovated to survive in the market. Large companies such as Abbott and Medtronic have made numerous mergers, acquisitions, and partnerships to gain market dominance while adhering to organic growth strategies. The manufacturers of insulin delivery devices are spending a huge amount on the R&D of the devices. For example, Novo Nordisk partnered with Abbott Diabetes Care, which may also assist in enabling insulin statistics to be shared between Novo Nordisk-connected insulin pens and digital fitness equipment well suited to the FreeStyle Libre portfolio of products. Mega Blockbuster Lantus, manufactured with the aid of Sanofi, led the basal insulin field.

Australia Diabetes Drugs and Devices Market Leaders

  1. Medtronics

  2. Roche

  3. NovoNordisk

  4. Sanofi

  5. Omnipod

  6. *Disclaimer: Major Players sorted in no particular order
Australia Diabetes Drugs and Devices Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Australia Diabetes Drugs and Devices Market News

  • March 2023: The Albanese Government extended access to Fiasp insulin and Fiasp FlexTouch via the Pharmaceutical Benefits Scheme for six months. Under the arrangements, people with a current prescription for Fiasp can access it for the next six months.
  • November 2022: Eli Lilly and Company announced that it would roll out its first connected platform, the Tempo Personalized Diabetes Management Platform. The technology aims to help adults with type 1 or 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins. The platform consists of three key components - the Tempo Smart Button, a compatible app, and a prefilled insulin pen, Tempo Pen. They work together to deliver personalized guidance for adults with diabetes.

Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Dynamics
    • 4.2.1 Market Drivers
    • 4.2.2 Market Restraints
  • 4.3 Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Suppliers
    • 4.3.2 Bargaining Power of Consumers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Threat of Substitute Products and Services
    • 4.3.5 Intensity of Competitive Rivalry

5. Market Segmentation (Market Size by Value - USD)

  • 5.1 Devices
    • 5.1.1 Monitoring Devices
    • 5.1.1.1 Self-monitoring Blood Glucose Devices
    • 5.1.1.2 Continuous Blood Glucose Monitoring
    • 5.1.2 Management Devices
    • 5.1.2.1 Insulin Pump
    • 5.1.2.2 Insulin Syringes
    • 5.1.2.3 Insulin Cartridges
    • 5.1.2.4 Disposable Pens
  • 5.2 Drugs
    • 5.2.1 Oral Anti-Diabetes Drugs
    • 5.2.2 Insulin Drugs
    • 5.2.3 Combination Drugs
    • 5.2.4 Non-Insulin Injectable Drugs

6. Market Indicators

  • 6.1 Type-1 Diabetes Population
  • 6.2 Type-2 Diabetes Population

7. COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Novo Nordisk
    • 7.1.2 Medtronic
    • 7.1.3 Insulet
    • 7.1.4 Tandem
    • 7.1.5 Ypsomed
    • 7.1.6 Novartis
    • 7.1.7 Sanofi
    • 7.1.8 Eli Lilly
    • 7.1.9 Abbottt
    • 7.1.10 Roche
    • 7.1.11 Astrazeneca
    • 7.1.12 Dexcom
    • 7.1.13 Pfizer
  • *List Not Exhaustive
  • 7.2 Company Share Analysis

8. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments.
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Australia Diabetes Drugs and Devices Industry Segmentation

Patients with type 1 diabetes must be given insulin because their pancreas cannot process it. To control blood sugar levels, insulin must be given several times daily, such as when eating or drinking. Many people with type 2 diabetes also need to take antidiabetic drugs. These drugs include diabetes medications and injections, such as insulin. The Australia diabetes drugs and devices market is segmented by drugs (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), and devices (management devices such as insulin pumps, insulin pens, syringes, cartridges, and jet injectors, and monitoring devices including self-monitoring blood and continuous glucose monitoring). The report offers the value (in USD) and volume (in unit) for the above segments.

Devices Monitoring Devices Self-monitoring Blood Glucose Devices
Continuous Blood Glucose Monitoring
Management Devices Insulin Pump
Insulin Syringes
Insulin Cartridges
Disposable Pens
Drugs Oral Anti-Diabetes Drugs
Insulin Drugs
Combination Drugs
Non-Insulin Injectable Drugs
Need A Different Region or Segment?
Customize Now

Frequently Asked Questions

What is the current undefined size?

The undefined is projected to register a CAGR of greater than 3% during the forecast period (2025-2030)

Who are the key players in undefined?

Medtronics, Roche, NovoNordisk, Sanofi and Omnipod are the major companies operating in the undefined.

What years does this undefined cover?

The report covers the undefined historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the undefined size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Australia Diabetes Drugs and Devices Industry Report

Statistics for the 2025 Australia Diabetes Drugs and Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Australia Diabetes Drugs and Devices analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.